Pharmacological Inhibition of LONP1 Enhances the Immunogenic Features of Melanoma Cells Undergoing Endoplasmic Reticulum Stress

Background: Lon Peptidase 1 (LONP1) is a mitochondrial protease responsible for maintaining mitochondrial proteostasis and cellular adaptation to stress. Overexpression of LONP1 has been implicated in cancer progression across multiple malignancies. Given the critical role of LONP1 in cancer cell survival, we sought to determine whether its pharmacological inhibition could impair cancer cell adaptation to endoplasmic reticulum (ER) stress and promote immunogenicity-associated features. Methods: We used the B16-F10 murine melanoma cell line as an in vitro model to study the effects of Methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate (CDDO-Me), a pharmacological inhibitor of LONP1. ER stress was induced using Thapsigargin and Tunicamycin. Western blotting was employed to assess expression levels of target proteins. Flow cytometry was performed to evaluate surface markers, as well as intracellular probes. TIMER 2.0 and TNMplot databases were used to explore the clinical relevance of LONP1 expression in patients with cutaneous melanoma. Results: Our data demonstrate that ER stress upregulates LONP1 expression in B16-F10 melanoma cells. Pharmacological inhibition of LONP1 with CDDO-Me during ER stress leads to a significant accumulation of melanoma cells in the sub G1 phase associated with high surface exposure of calreticulin, MHC class I, and extracellular ATP release. In addition, treatment with CDDO-Me in the presence of ER stress impairs autophagic activity as evidenced by elevated LC3-II levels, and p62 accumulation. TNMplot shows an upregulation of LONP1 expression in malignant tissues compared to their normal counterparts across various cancer types. TIMER 2.0 reveals a negative correlation between LONP1 expression and markers of antitumor immunity. Conclusions: Collectively, these results provide mechanistic insights into the antitumor activity of CDDO-Me in stressed melanoma cells and support the therapeutic potential of targeting LONP1 in melanoma.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-16
DOI
https://doi.org/10.3390/biomedicines14112644
Primary Topic
Endoplasmic Reticulum Stress and Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacological Inhibition of LONP1 Enhances the Immunogenic Features of Melanoma Cells Undergoing Endoplasmic Reticulum Stress

Thomas Rodriguez, Mohammed L. Ibrahim, Dalia El‐Gamal, Brandon Bol et al.
1 links
Biomedicines
Endoplasmic Reticulum Stress and Disease
article

Pharmacological Inhibition of LONP1 Enhances the Immunogenic Features of Melanoma Cells Undergoing Endoplasmic Reticulum Stress

Thomas Rodriguez, Mohammed L. Ibrahim, Dalia El‐Gamal, Brandon Bol, Petros Martin Raygoza, Shaumik Patil, Jonathan Clement, Jordan Darling, Eslam Mohamed
article en

Abstract

Background: Lon Peptidase 1 (LONP1) is a mitochondrial protease responsible for maintaining mitochondrial proteostasis and cellular adaptation to stress. Overexpression of LONP1 has been implicated in cancer progression across multiple malignancies. Given the critical role of LONP1 in cancer cell survival, we sought to determine whether its pharmacological inhibition could impair cancer cell adaptation to endoplasmic reticulum (ER) stress and promote immunogenicity-associated features. Methods: We used the B16-F10 murine melanoma cell line as an in vitro model to study the effects of Methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate (CDDO-Me), a pharmacological inhibitor of LONP1. ER stress was induced using Thapsigargin and Tunicamycin. Western blotting was employed to assess expression levels of target proteins. Flow cytometry was performed to evaluate surface markers, as well as intracellular probes. TIMER 2.0 and TNMplot databases were used to explore the clinical relevance of LONP1 expression in patients with cutaneous melanoma. Results: Our data demonstrate that ER stress upregulates LONP1 expression in B16-F10 melanoma cells. Pharmacological inhibition of LONP1 with CDDO-Me during ER stress leads to a significant accumulation of melanoma cells in the sub G1 phase associated with high surface exposure of calreticulin, MHC class I, and extracellular ATP release. In addition, treatment with CDDO-Me in the presence of ER stress impairs autophagic activity as evidenced by elevated LC3-II levels, and p62 accumulation. TNMplot shows an upregulation of LONP1 expression in malignant tissues compared to their normal counterparts across various cancer types. TIMER 2.0 reveals a negative correlation between LONP1 expression and markers of antitumor immunity. Conclusions: Collectively, these results provide mechanistic insights into the antitumor activity of CDDO-Me in stressed melanoma cells and support the therapeutic potential of targeting LONP1 in melanoma.

BiomedicinesVol. 14(11)
University of Pittsburgh (US), Loma Linda University (US), UPMC Hillman Cancer Center (US), University of Pittsburgh Medical Center (US), California Northstate University (US)
Good health and well-being
Endoplasmic Reticulum Stress and Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon